Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
UBS
US Department of Justice
US Army
McKinsey
Chinese Patent Office
Covington
Citi
McKesson
Federal Trade Commission

Generated: August 22, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 5,942,519 protect, and when does it expire?


Patent ► Subscribe protects PROSCAR and is included in one NDA.

This patent has six patent family members in five countries.

Summary for Patent: ► Subscribe

Title: Prevention of precipitated acute urinary retention
Abstract:This invention is concerned with the prevention of precipitated acute urinary retention in a subject male susceptible thereto by the administration of an inhibitor of 5.alpha.-reductase to the subject. The present invention also provides for a method of reducing the risk of precipitated acute urinary retention by the administration of a 5.alpha.-reductase inhibitor to the subject at risk therefor.
Inventor(s): Waldstreicher; Joanne (Scotch Plains, NJ)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:09/178,138
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Merck
PROSCAR
finasteride
TABLET;ORAL020180-001Jun 19, 1992ABRXYesYes► Subscribe► Subscribe TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office1032400► Subscribe
Japan2001521000► Subscribe
Canada2308070► Subscribe
Australia731576► Subscribe
Australia1279099► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Teva
Medtronic
Cantor Fitzgerald
UBS
Cerilliant
Express Scripts
Covington
US Army
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot